• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    In order to maintain the stability of the medium, nitrate RHS of sodium or potassium is reacted with aqueous or concentrated nitric acid at 20–25 ° C until a pH of less than 1 is reached. Sodium or potassium nitrite is taken in an amount of 0.01–5 mg / ml, and nitric acid 6 -10 µmuL.
    公开号:SU1382394A3
    申请号:SU802990878
    申请日:1980-09-26
    公开日:1988-03-15
    发明作者:Марди Шальва；Феликс Лихти Хайнц；Баумгартнер Гидо；Гартайц Даниель；Юдд Клод；Вайнер Мюррей
    申请人:Золько Базель Аг (Фирма)；
    IPC主号:
    专利说明:

    i WITH
    with
    00
    to
    00


    cm
    ten
    The invention relates to cosmetics and medicine, in particular, to dermatology.
    The aim of the invention is to increase the stability of the agent.
    The goal is achieved by reacting sodium or potassium nitrite with aqueous or concentrated nitric acid at 20–25 ° C until a pH is lower, while sodium or potassium nitrite is taken in an amount of 0.01–5 mg / ml, and nitric acid is in the amount of 6-10 µmol / ml.
    The method is carried out as follows.
    A metal nitrite soluble in an aqueous solution of nitric acid in an amount of 0.01–5 mg of nitrite per 1 ml of the final solution is reacted with nitric acid at its concentration in an aqueous solution of 6–10 µmol Uml or more concentrated solution of nitric acid at room or 25 more low temperature. The resulting solution is diluted with water to obtain a concentration of 6-JO micromol of nitrous K21 SLOT per 1 ml of solution and pH less than 1.
    Example 1. 10 mg of sodium nitrite are placed in a 1000 ml volumetric flask. 100 ml of deionized water are added at 20 ° C and stirred until the crystals completely dissolve. Then slowly and with constant rotation of the flask is added to a solution of 454 ml of concentrated (.65%) nitric acid and immediately thereafter 0000 - 400 ml of deionized water. When the temperature reaches 25 ° C or even higher, the flask outside is cooled with cold tap water until the temperature inside
    the contents of the flask would always have the same temperature. Then, while rotating, it is filled with water at a temperature up to the mark. The pH value is about 0.5.
    Example 5.0 mg of sodium nitrite is placed in a 1000 ml volumetric flask. 400 ml of water are added at 23 ° C and the magnetic stirrer bar is introduced, ensuring the dissolution of the crystals by stirring. 100 ml of ice water and 420 ml of ice-concentrated nitric acid are mixed in a separate container. The mixture is left under normal conditions for one hour. It is then added slowly and with constant stirring to the contents of the flask. Remove
    20 with a magnetic stirrer, rinse it with a small amount of water and fill the flask with water at a temperature of 23 ° C to the mark. The pH value is about 0.5.
    Example4. JOOr ice, 150 ml of water and 390 ml of concentrated nitric acid, are fed into a 1000 ml volumetric flask. After dissolving the ice, add the medpa when rotating.
    30 flasks of a solution of 5.0 potassium nitrite in 300 ml of water, at 20–25 ° C, should the temperature inside the flask not rise above + 25 ° C. The flask is then filled with water at 25 ° C to 1000 ml. The pH of the solution is about 0.5.
    The proposed agent is a clear, colorless liquid. If stored in an open vessel at room temperature, biological tests in less than two weeks will give negative results (due to decomposition of nitric acid). Unlimited us35
    40
    the flasks will again reach 20 ° C. In the stability of the product obtained, the volume can be filled de-ionized by storage by storage.
    water to 1000 ml and evenly stirred, for which the flask is rotated repeatedly. The pH value is about 0.5.
    Both pm and m 2. 250 ml of water at 22 ° C and 10 mg of potassium nitrite are fed into a 1000 ml volumetric flask. The crystals are dissolved by shaking. After that, with constant rotation of the flask, 380 ml of concentrated acetic acid is added and from time to time the flask is immersed in a water bath with a TF temperature of 22 ° C, so that
    0
    five
    the contents of the flask would always have the same temperature. Then, while rotating, it is filled with water at a temperature up to the mark. The pH value is about 0.5.
    Example 5.0 mg of sodium nitrite is placed in a 1000 ml volumetric flask. 400 ml of water are added at 23 ° C and the magnetic stirrer bar is introduced, ensuring the dissolution of the crystals by stirring. In a separate container, 100 ml of ice water and 420 ml of ice-concentrated nitric acid are mixed. The mixture is left under normal conditions for one hour. It is then added slowly and with constant stirring to the contents of the flask. Remove
    0 magnetic stirrer, rinse it with a small amount of water and fill the flask with water with a temperature of 23 ° C to the mark. The pH value is about 0.5.
    Example4. JOOr ice, 150 ml of water and 390 ml of concentrated nitric acid, are fed into a 1000 ml volumetric flask. After dissolving the ice, add the medpa when rotating.
    0 flasks a solution of 5.0 potassium nitrite in 300 ml of water at 20–25 ° C, so that the temperature inside the flask does not rise above + 25 ° C. The flask is then filled with water at 25 ° C to 1000 ml. The pH of the solution is about 0.5.
    The proposed agent is a clear, colorless liquid. If stored in an open vessel at room temperature, biological tests in less than two weeks will give negative results (due to decomposition of nitric acid). Unlimited us5
    0
     stability of the obtained product can be achieved by storing it with
    0-10 s, for example, in the refrigerator.
    An agent for the removal of pathological skin lesions can be applied both in cosmetics and in medicine, and the cosmetic field of application extends to all benign cosmetic interfering skin changes if they are superficial and do not exceed a certain size.
    The main area of application of the drug in medicine is suitable in dermatology, oncology, and urology.
    ophthalmology and gynecology. It can be applied externally and under the supervision of a physician.
    The agent, when applied locally, results in immediate lifetime fixation of the tissue with which it is in contact. Its effect is found by coloration from white to yellow to gray treated mertha. The dead piece of fabric dries out and is stained due to the increasing mummification in a dark brown color. The mummified rind after 2-3 weeks. spontaneously repeats. The cure proceeds without complications, namely without a secondary infection, and quickly. At the same time, disfiguring scars do not remain on the skin and tissues do not stretch.
    The agent is applied strictly locally by topical application or due to other forms of local treatment of treatment to the corresponding pathologically changed parts of the tissue that must be removed. From the center of the lesion to the periphery are distributed from one to several droplets of the solution and, due to slight cauterization, the EYE is introduced into the affected site.
    Removal of the skin lesions is painless, sometimes a slight burning sensation is felt. The slight reddening of the environment of the treated area of skin is normal and does not require any special treatment; ; and, With a stronger reaction of the environment or itching, a steroid cream or anesthetic ointment can be applied locally.
    The agent is not absorbed and does not have any side effects. No sensitization or allergic reactions are observed.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    A method of producing a cosmetic agent for removing pathological skin lesions by interacting with VIA ingredients, in order to increase stability, sodium or potassium nitrite is subjected to interaction with aqueous or concentrated nitric acid at 20-25 ° C until pH is less than J, while sodium or potassium nitrite is taken in an amount of 0, OJ is 5 mg / ml, and nitric acid in an amount of 6-JO micromol / ml.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1382394A3|1988-03-15|Method of producing cosmetic compound for removing skin pathologic formations
    US5432053A|1995-07-11|Solution for conservation of living organs
    PL96082B1|1977-12-31|METHOD FOR THE PRODUCTION OF NEW BIS- / BIHYDROXYPROPYLAMIDES / 5-HYDROXYPROPIONYLAMINO-2,4,6-TRIODO-ISOPHTAL
    KR100297965B1|2001-10-24|Skin and mucous solution
    BR112012017157B1|2018-12-11|prophylactic or pigment enhancing agent.
    CN106187793A|2016-12-07|5 aminolevulinic acids and the salt compound of derivant thereof and application
    RU2261243C1|2005-09-27|Zinc and aliphatic halogen-carboxylic acid salts for treatment of skin neoplasm and visible mucosa tissues
    EP0572963B1|2000-09-20|Sclerosing solution
    RU2163810C1|2001-03-10|Composition for removal of benign neoplasms on skin and mucosa and method of its preparing
    RU2163816C1|2001-03-10|Method of preparing agent for treatment of non-oncological pathology of body
    Sutton1937|Pigmentation of the skin due to iron | applied locally
    RU2070037C1|1996-12-10|Process for preparing composition having hepatoprotector and cardioprotector activity
    JP2002080376A|2002-03-19|Biologically active agent and medicine
    AU694463B2|1998-07-23|Composition for curing lesioned tissue, process for producing the same, and use thereof
    Greenberg et al.1929|Epididymitis associated with typhoid
    RU2089197C1|1997-09-10|Preparation exhibiting the prolonged effect and a method of its preparing
    RU2132184C1|1999-06-27|Method of preparing composition "zhiroform-plus" for treatment and prophylaxis of endometritis in cows
    Mirgorod et al.2019|Grounds for selection of bases for preparing gel with phytos complex for treatment of skin diseases
    RU2123326C1|1998-12-20|Pharmaceutical composition with photosensibilizing agent
    CN1371675A|2002-10-02|Skin protection spot-removing cream and preparation method thereof
    RU2112506C1|1998-06-10|Salicylic ointment
    US5204091A|1993-04-20|Method for combatting foot odors
    GR0|PHYSIOLOGICAL CHENISTRY. 92 I
    SU1600765A1|1990-10-23|Method of treating atrophy of optic herve
    KR930010622B1|1993-11-02|Composition for the reduction of phlebectasia
    同族专利:
    公开号 | 公开日
    IL61136A|1984-02-29|
    PL226939A1|1981-08-21|
    EP0026532A2|1981-04-08|
    DK407480A|1981-03-28|
    EP0026532A3|1981-08-19|
    DE3071629D1|1986-07-10|
    AU538878B2|1984-08-30|
    KR830003210A|1983-06-18|
    ZA805990B|1981-09-30|
    IN154851B|1984-12-15|
    AT20183T|1986-06-15|
    ES8107020A1|1981-10-01|
    FI73129C|1987-09-10|
    AU6275880A|1981-04-09|
    IL61136D0|1980-11-30|
    PL133116B1|1985-05-31|
    US4595591A|1986-06-17|
    DK161012C|1991-10-28|
    AR224654A1|1981-12-30|
    EP0026532B1|1986-06-04|
    JPH0129773B2|1989-06-14|
    ES495330A0|1981-10-01|
    JPS5659706A|1981-05-23|
    CA1155058A|1983-10-11|
    DK161012B|1991-05-21|
    FI73129B|1987-05-29|
    PH18810A|1985-09-27|
    FI803037A|1981-03-28|
    CH629100A5|1982-04-15|
    KR850001724B1|1985-12-07|
    GR70008B|1982-07-23|
    EG15021A|1985-06-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    RU2482856C2|2011-08-05|2013-05-27|Общество С Ограниченной Ответственностью "Оксигон"|Complex compound of zinc 2-chloropropionate and 2-chloropropionic acid, pharmaceutical composition for treating skin diseases, method for preparing it and method for treating skin, nail and visible mucosal disorders|US3988470A|1974-02-25|1976-10-26|Scott Eugene J Van|Treatment of palmar and plant disturbed keratosis|
    US3879537A|1973-09-04|1975-04-22|Scott Eugene J Van|Treatment of ichthyosiform dermatoses|EP0151201B1|1982-10-08|1986-11-12|Zvonko Pestelic|Keratolytic composition suitable for removing warts|
    CH673225A5|1986-04-22|1990-02-28|Sanosil Ag|
    US4681687A|1986-10-20|1987-07-21|Nalco Chemical Company|Use of alkali metal nitrites to inhibit H2 S formation in flue gas desulfurization system sludges|
    US4758426A|1987-06-11|1988-07-19|Ramsdell Bruce V|Therapeutic toilet solution and method of dispersion|
    US5053024A|1989-10-23|1991-10-01|Israel Dvoretzky|Application system and method for treating warts|
    GB9308103D0|1993-04-20|1993-06-02|Unilever Plc|Cosmetic composition|
    MY128187A|1993-06-23|2007-01-31|Icn Switzerland Ag|Preparation for skin and mucous membrane|
    US5456904A|1993-06-28|1995-10-10|The Procter & Gamble Company|Photoprotection compositions comprising certain chelating agents|
    US5407958A|1993-07-30|1995-04-18|Beauticontrol Cosmetics, Inc.|Therapeutic skin composition|
    US6418556B1|1993-09-09|2002-07-09|United Video Properties, Inc.|Electronic television program guide schedule system and method|
    FR2715845B1|1994-02-04|1996-03-29|Oreal|Cosmetic and / or dermatological composition containing vinegar.|
    US6709681B2|1995-02-17|2004-03-23|Aberdeen University|Acidified nitrite as an antimicrobial agent|
    DE69533714T2|1994-12-20|2005-03-24|Unilever N.V.|Lactate dehydrogenase inhibitors in cosmetic products|
    SE9700617D0|1997-02-21|1997-02-21|Kjell Alving|New composition|
    GB9905425D0|1999-03-09|1999-05-05|Queen Mary & Westfield College|Pharmaceutical composition|
    US6585742B2|2001-05-08|2003-07-01|Dowling B. Stough|Wart removal method and device|
    US20060200174A1|2001-05-08|2006-09-07|Stough Dowling B|Wart removal method and device|
    EP1455888B1|2001-08-29|2009-04-29|PharmaKodex Limited|Topical administration device|
    US7128903B2|2001-10-03|2006-10-31|Innovative Pharmaceutical ConceptsInc.|Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucous membranes and methods and kits using same|
    US20030175362A1|2002-01-07|2003-09-18|Kross Robert D.|Disinfecting nitrous acid compositions and process for using the same|
    MXPA04008912A|2002-03-22|2005-02-28|Suarez Mendoza Ramon|Outflow tension valve for toilet cisterns and/or general use thereof.|
    US7780992B2|2002-12-08|2010-08-24|Tareq Abduljalil Albahri|Antiviral medicament|
    UA82254C2|2003-12-03|2008-03-25|Валодя Падиурашвили|Formulation and process for preparation of composition, pharmaceutical composition and use thereof|
    US7258875B2|2003-12-04|2007-08-21|Chiou Consulting, Inc.|Compositions and methods for topical treatment of skin infection|
    US7311928B2|2003-12-09|2007-12-25|Briant Burke|Topical compositions containing tea tree oil for treatment of viral lesions|
    AU2006204585B2|2005-01-06|2011-04-14|Bennett, David Mr|Composition and method for treatment of residues in pumping, bore, and reticulation equipment|
    US7776809B2|2005-01-06|2010-08-17|David Bennett|Composition and method for treatment of residues in pumping, bore and reticulation equipment|
    ES2373772T3|2008-01-25|2012-02-08|Auriga International|PHARMACEUTICAL COMPOSITION THAT INCLUDES �? NIDOTIC CID AND A CINC SALT AND ITS MEDICAL DEVICE FOR THE TREATMENT OF SKIN INJURIES.|
    RU2440816C1|2010-12-09|2012-01-27|Общество С Ограниченной Ответственностью "Оксигон"|Medication, method of its obtaining and method of application|
    US9446068B2|2011-04-22|2016-09-20|Obschestvos S Ogranitchennoi Otvetstvennostju “Oxygon”|Method of production of the stable selenium-comprising pharmaceutical composition with a high selenium level|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    CH871379A|CH629100A5|1979-09-27|1979-09-27|Hautpraeparat.|
    [返回顶部]